Clik here to view.
Hepalink Announces the Appointment of Healthcare Senior Executive Mr. Frank...
SHENZHEN, China Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE: 002399), a China-based global pharmaceutical company targeting high-mortality diseases with significant unmet medical needs,...
View ArticleClik here to view.
TÜV Rheinland Launches Eyesafe Display Standard, New Requirements Guide...
SHANGHAI The international independent third-party testing, inspection, and certification organization, TÜV Rheinland Group, has announced the launch of the Eyesafe Display Standard. It is based on...
View ArticleClik here to view.
TÜV Rheinland Launches Eyesafe Display Standard, New Requirements Guide...
SHANGHAI The international independent third-party testing, inspection, and certification organization, TÜV Rheinland Group, has announced the launch of the Eyesafe Display Standard. It is based on...
View ArticleClik here to view.
TFF Pharmaceuticals Announces Engagement of Torreya Partners, LLC as...
AUSTIN, Texas TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film...
View ArticleClik here to view.
Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise...
SAN FRANCISCO & SEONGNAM, South Korea Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage...
View ArticleClik here to view.
キリンホールディングス株式会社：資本市場とのコミュニケーションの進捗報告について
東京 （ビジネスワイヤ） — キリンホールディングス株式会社（東証：2503）（社長 磯崎功典）は、3月3日、東京にてインベスターデイを開催し、キリングループの持続的成長に向けて、資本市場との相互理解を深めました。 当社、並びに主力事業会社の社長が登壇し、 KV 2027 （長期経営構想「キリングループ・ビジョン2027」）...
View ArticleClik here to view.
Kirin Holdings Provides Update to Capital Markets
TOKYO Kirin Holdings Co., Ltd. (“Kirin” or the “the Company”) (TOKYO: 2503) held an Investor Day in Tokyo on March 3 to facilitate mutual understanding with the capital markets on Kirin’s long-term...
View ArticleClik here to view.
Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to...
TOKYO Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has entered into...
View ArticleClik here to view.
Notice of Capital and Business Alliance Between Heartseed and MEDIPAL HOLDINGS
TOKYO Tokyo-based Heartseed Inc. (“Heartseed”), a Keio University-originated biotechnology company developing induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine, and MEDIPAL...
View ArticleClik here to view.
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition...
View ArticleClik here to view.
Brii Biosciences Provides Funding to Columbia University for Research on...
DURHAM, N.C. & BEIJING Brii Biosciences (“Brii Bio”) and Columbia University have entered into a memorandum of understanding through which Brii Bio will provide funding to support research to be...
View ArticleClik here to view.
Hot Topics Recap: Coronavirus
NEW YORK Following are the latest Coronavirus news releases and story ideas for reporters, bloggers and media outlets. These recaps, curated by Business Wire, provide reporters and bloggers around...
View ArticleClik here to view.
2万1848人の高リスクPCI患者を対象とした研究でPVAD（Impella）使用患者での死亡／合併症リスク低減を実証
米マサチューセッツ州ダンバース （ビジネスワイヤ） — 経皮的左室補助装置（PVAD /...
View ArticleClik here to view.
New Treatment for Parkinson’s Disease Developed at NTHU
HSINCHU, Taiwan Ultrasound is widely used for conducting physical examinations, and plans are underway for expanding its application to the treatment of Parkinson’s disease, dementia, and diabetes....
View ArticleClik here to view.
武田提供3期TOURMALINE-MM2试验的更新
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天发布了TOURMALINE-MM2研究的结果，该研究旨在评估不适合移植的多发性骨髓瘤新诊断患者在来那度胺和地塞米松基础上添加NINLARO™...
View ArticleClik here to view.
Clik here to view.
Next-Gen Artificial Intelligence (AI) Company Graphen Monitors Genomic...
NEW YORK Graphen, Inc., a startup building AI solutions inspired by full brain functionality, today announced its AI gene evolution pathway analysis of the virus that causes the Coronavirus disease,...
View ArticleClik here to view.
RELIEF THERAPEUTICS Holding SA (SIX: RLF)在即将召开的股东年会上宣布提议Jonathan Javitt,...
日内瓦 (美国商业资讯)– RELIEF THERAPEUTICS Holding SA（SIX-RLF，以下简称“Relief”或“公司”）今天宣布，将在2020年6月19日召开的股东年会上推选Jonathan C. Javitt, MD, MPH教授担任副董事长。Javitt教授已加入Relief Therapeutics团队担任顾问，他入职董事会后将无缝协调Relief开发RLF-100...
View ArticleClik here to view.
The Kidney Kid Superhero Initiative Goes International on World Kidney Day
HONG KONG Fresenius Medical Care, the world’s leading provider of dialysis products and services, has today announced the international and digital expansion of its highly successful Asia...
View ArticleClik here to view.
Harbour BioMed Raises $75 Million Series B+ Venture Capital Financing to...
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced successful completion of its Series B+ round financing of $75 million to accelerate the...
View Article